Cargando…
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells
BACKGROUND: Although pioglitazone, a well‐known anti‐diabetic agent, has recently established itself as a pillar of cancer treatment, its therapeutic value could be attenuated by the aberrant activation of the PI3K/Akt pathway. AIM: To evaluate whether the PI3K/Akt suppression in leukemic cells coul...
Autores principales: | Esmaeili, Shadi, Yousefi, Amir‐Mohammad, Delshad, Mahda, Bashash, Davood |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009912/ https://www.ncbi.nlm.nih.gov/pubmed/36398521 http://dx.doi.org/10.1002/mgg3.2106 |
Ejemplares similares
-
Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination
por: Delshad, Mahda, et al.
Publicado: (2022) -
Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells
por: Esmaeili, Shadi, et al.
Publicado: (2021) -
PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest
por: Sadeghi, Soroush, et al.
Publicado: (2020) -
The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19
por: Delshad, Mahda, et al.
Publicado: (2021) -
Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity
por: Delshad, Mahda, et al.
Publicado: (2021)